| 0 (0%) | 09-27 11:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.73 | 1-year : | 33.55 |
| Resists | First : | 24.6 | Second : | 28.73 |
| Pivot price | 23.01 |
|||
| Supports | First : | 20.52 | Second : | 18 |
| MAs | MA(5) : | 23.08 |
MA(20) : | 22.23 |
| MA(100) : | 14.44 |
MA(250) : | 12.02 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.6  |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 70.5 |
| RSI | RSI(14): 74.4 |
|||
| 52-week | High : | 24.6 | Low : | 5.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STOK ] has closed below upper band by 1.1%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.38 - 24.48 | 24.48 - 24.58 |
| Low: | 22.77 - 22.87 | 22.87 - 22.97 |
| Close: | 23.97 - 24.15 | 24.15 - 24.33 |
Wed, 24 Sep 2025
Meet Stanzin Jigmed Namgyal, Prince Of Ladakh: A Journey Inside His Historic Stok Palace, Exploring Royal Heri - Times Now
Mon, 22 Sep 2025
First Week of May 2026 Options Trading For Stoke Therapeutics (STOK) - Nasdaq
Tue, 16 Sep 2025
135,300 Shares at $23.40: Stoke Therapeutics Awards Million-Dollar Stock Options Package to New Hires - Stock Titan
Wed, 10 Sep 2025
Stoke Therapeutics (STOK): Gauging Valuation Following Promising New Dravet Syndrome Study Data - simplywall.st
Wed, 10 Sep 2025
Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug - Yahoo Finance
Sun, 17 Aug 2025
I Tried 10 Store-Bought Cold Brew Coffees and This Is the Only One Worth Buying - Allrecipes
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 55 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 118.4 (%) |
| Shares Short | 10,740 (K) |
| Shares Short P.Month | 11,430 (K) |
| EPS | 0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.11 |
| Profit Margin | 26.2 % |
| Operating Margin | -197.6 % |
| Return on Assets (ttm) | 7.2 % |
| Return on Equity (ttm) | 18.1 % |
| Qtrly Rev. Growth | 186 % |
| Gross Profit (p.s.) | 3.64 |
| Sales Per Share | 3.64 |
| EBITDA (p.s.) | 0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 43 (M) |
| PE Ratio | 27.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.94 |
| Price to Sales | 6.61 |
| Price to Cash Flow | 21.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|